Combined Microwave Ablation and Minimally Invasive Open Decompression for the Management of Thoracic Metastasis in Breast CancerJune 29, 2018
[Cancer Management and Research] An investigation into the efficacy of microwave ablation and minimally invasive open decompression treatment for breast cancer with thoracic metastases.
In an analysis of data from the SEER program, researchers determined that early detection of prostate cancer has let to an improvement in the number of men presenting with metastatic prostate cancer.
Baseline tumor size and PD-L1 status were independently associated with the likelihood of a complete response.
A comparison study presented at the 2017 SABCS sought to determine the effectiveness of bisphosphonates with denosumab for skeletal-related events in women with breast cancer metastases to bone.
A study examines the role of two hypoxia-responsive microRNAs, miR-25 and miR-93, in establishing an immunosuppressive tumour microenvironment.
Complete surgical metastasectomy correlated with increased survival in patients with metastatic renal cell carcinoma (mRCC) compared with incomplete surgical metastasectomy.
Might a Chemical from Celery and Broccoli One Day Yield a New Drug to Prevent Breast Cancer Metastasis?February 07, 2017
Investigators report on their findings from preclinical studies of luteolin injections to prevent lung metastases of triple-negative breast cancer.
CDK 4/6 inhibitors, currently approved for the treatment of estrogen-positive breast cancer, were found to inhibit metastasis in triple-negative breast
Atezolizumab (Tecentriq) is approved by the FDA for the treatment of metastatic NSCLC in specific cases or tumors with EGFR or ALK gene mutations.
[Journal of Gastrointestinal Oncology] This research examines factors associated with survival in patients with brain metastasis from esophageal cancer.
Dab2 is an endocytic adaptor and tumor suppressor whose expression occurs during the epithelial-mesenchymal transition, which is mediated by TGF-beta. This study sought to understand how Dab2 regulates apoptosis.
Metastatic capabilities of pancreatic cancer might arise before tumors even form. Metastasis and advanced stage of disease at diagnosis are attributed to low survival rates for pancreatic cancer.
The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.
Palbociclib Plus Fulvestrant Provides Significant Benefit in Hormone Receptor-Positive Metastatic Breast CancerJune 03, 2016
ESR1 mutations detected in plasma circulating tumor DNA were identified in a high percentage of patients with hormone receptor-positive metastatic breast cancer, confirming an important role in endocrine resistance, according to an analysis of data from the phase 3 PALOMA-3 reported at the 2016 ASCO Annual Meeting.
ESR1 Mutations Predict Worse Outcome in HR-positive Metastatic Breast Cancer Treated with Aromatase InhibitorsJune 03, 2016
The presence of circulating ESR1 somatic mutations at disease progression in patients with HR-positive metastatic breast cancer treated with first-line AIs represent a strong and independent poor prognostic value for overall survival but no predictive value, a study presented at the 2016 ASCO Annual Meeting has found.
The geometric shape of the outside edge of a cancerous tumor plays a significant role in activating tumor-seeding cells that lead to metastasis.
A low-dose of aspirin could increase survival by up to 20% and help stop metastasis for patients receiving cancer treatment.
A small, phase I clinical trial indicates the experimental drug guadecitabine is safe in combination with the chemotherapy drug irinotecan, and it may overcome resistance to irinotecan in patients with metastatic colorectal cancer.
A new biomarker measurement might improve the accuracy of prognostic testing and precision medicine in uveal melanoma.
Adrenaline acted on breast cancer cells via the cell surface beta2-adrenoceptor to promote disease growth and invasion, suggesting that beta-blockers might be helpful as adjuvant therapy for patients with aggressive breast cancer.
Adding radiotherapy to chemotherapy and surgery reduced the number of local disease recurrences but did not affect distant recurrences or survival.
Cancer metastasis is dynamically regulated by cancer-associated fibroblasts (CAFs), a cancer-promoting component in the tumor microenvironment. Eliminating the CAFs after 10 days dramatically increases the risk of the primary tumor metastasis to the lungs and bones in a mouse model.
Current sequencing technology has enabled an analysis of cancer evolution that directs research attention away from the search for genes that enable metastasis and toward genes that are mutated early during tumorigenesis.
A gene previously thought only to be expressed in the brain, GABAA receptor alpha3 (Gabra3), promotes breast cancer migration, invasion, and metastasis.
PRAME mRNA expression is independent prognostic biomarker in Class 1 uveal melanoma.
The protein EPHA2, a receptor on the lining of blood vessels, controls how breast cancer cells metastasize around the body. These findings shed light on how cancer cells exit blood vessels to enter a new part of the body.
Researchers visualized the origins of cancer from the first affected cell through its spread in a live animal: the zebrafish. This research may change scientific understanding of melanoma and other cancers leading to new treatments that can be administered before the cancer has taken hold.
No evidence that interferon is necessary or helpful in cases of melanoma with minimal metastasis to the lymph nodes, according to the final results of the Sunbelt Melanoma Trial.
Men with prostate cancer and bone metastases that have experienced at least one skeletal-related event (SRE) show worse survival, according to a recent study.
Circulating Tumor DNA More Effective Than LDH at Detecting Metastatic Melanoma Progression, RecurrenceJanuary 25, 2016
Metastatic melanoma disease activity may be monitored via circulating tumor DNA, which has higher sensitivity than lactate dehydrogenase for detecting disease progression.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|